- Home
- CUE vs ATLX Comparison
CUE vs ATLX Comparison
Compare CUE & ATLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | ATLX |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 124.5M |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CUE | ATLX |
|---|---|---|
| Price | $30.34 | $2.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $120.00 | $12.00 |
| AVG Volume (30 Days) | 137.0K | ★ 376.9K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | 47.08 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,466,000.00 | $92,491.00 |
| Revenue This Year | N/A | $64,564.67 |
| Revenue Next Year | N/A | $785.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $2.74 |
| 52 Week High | $45.50 | $8.25 |
Technical Indicators
Market Signals| Indicator | CUE | ATLX |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 30.29 |
| Support Level | $24.49 | N/A |
| Resistance Level | $32.82 | $3.92 |
| Average True Range (ATR) | 4.17 | 0.17 |
| MACD | -0.22 | -0.01 |
| Stochastic Oscillator | 31.96 | 1.50 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About ATLX Atlas Lithium Corporation
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.